Chemomab Therapeutics (CMMB) Equity Ratio (2017 - 2025)

Chemomab Therapeutics (CMMB) has 9 years of Equity Ratio data on file, last reported at 0.89 in Q4 2025.

• For the quarter ending Q4 2025, Equity Ratio rose 11.91% year-over-year to 0.89; the trailing twelve-month figure through Dec 2025 stood at 0.89 (up 11.91% YoY), and the FY2025 full-year result was 0.89, up 11.91% from the prior year.
• Equity Ratio for Q4 2025 stood at 0.89, down from 0.91 in the prior quarter.
• Across five years, Equity Ratio topped out at 0.97 in Q3 2021 and bottomed at 0.69 in Q2 2024.
• The 5-year median for Equity Ratio is 0.86 (2022), against an average of 0.85.
• Peak annual rise in Equity Ratio reached 29.9% in 2021, while the deepest fall reached 38.56% in 2021.
• A 5-year view of Equity Ratio shows it stood at 0.96 in 2021, then slipped by 11.93% to 0.84 in 2022, then retreated by 8.78% to 0.77 in 2023, then gained by 4.0% to 0.8 in 2024, then climbed by 11.91% to 0.89 in 2025.
• The last three Equity Ratio figures came in at 0.89 (Q4 2025), 0.91 (Q3 2025), and 0.87 (Q2 2025), per Business Quant data.

Peer Comparison